Last updated on November 2019

A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Epilepsy | Myoclonic Epilepsy | Lennox Gastaut Syndrome
  • Age: Between 2 - 17 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Male and female patients aged greater than or equal to (>=) 2 and less than or equal to (<=) 17 years
  2. Clinical diagnosis of Dravet Syndrome or LGS
  3. Weight of >=10 kilogram (kg) at the Screening visit
  4. Currently taking 1 to 4 anti-epileptic drugs (AED) at a stable dose
  5. Failed to become and remain seizure free with trials of at least 2 AEDs

Exclusion Criteria:

  1. Has been admitted to a medical facility and intubated for treatment of status epilepticus 2 or more times in the 3 months immediately prior to the screening visit
  2. Non-epileptic events that cannot be reliably distinguished from epileptic seizures
  3. Participation in a clinical study involving another study drug in the previous month

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.